Wall Street Zen Upgrades Alto Neuroscience (NYSE:ANRO) to Sell

Alto Neuroscience (NYSE:ANRO) was upgraded by analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a research report issued on Saturday.

Several other research firms have also recently commented on ANRO. Bank of America initiated coverage on Alto Neuroscience in a research note on Tuesday, May 5th. They issued a “buy” rating and a $35.00 target price for the company. HC Wainwright reaffirmed a “buy” rating on shares of Alto Neuroscience in a research note on Wednesday, June 17th. Wedbush raised their price target on Alto Neuroscience from $21.00 to $24.00 and gave the company a “neutral” rating in a report on Thursday, May 14th. Robert W. Baird lowered their price objective on Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating for the company in a research report on Monday, May 18th. Finally, Chardan Capital reiterated a “buy” rating and issued a $30.00 price objective on shares of Alto Neuroscience in a research report on Wednesday, April 22nd. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $35.25.

Alto Neuroscience Trading Up 0.0%

ANRO opened at $27.54 on Friday. Alto Neuroscience has a 1-year low of $2.72 and a 1-year high of $28.85. The stock has a market capitalization of $966.52 million, a PE ratio of -11.38 and a beta of 1.04. The company has a current ratio of 20.52, a quick ratio of 20.52 and a debt-to-equity ratio of 0.07. The firm has a 50-day moving average price of $23.17 and a two-hundred day moving average price of $21.20.

Alto Neuroscience (NYSE:ANRO) last announced its earnings results on Wednesday, May 13th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.24). As a group, equities analysts anticipate that Alto Neuroscience will post -3.01 earnings per share for the current fiscal year.

Institutional Trading of Alto Neuroscience

Several institutional investors and hedge funds have recently made changes to their positions in the business. Commodore Capital LP bought a new position in shares of Alto Neuroscience in the 4th quarter worth $32,453,000. Perceptive Advisors LLC grew its stake in shares of Alto Neuroscience by 1,048.5% during the fourth quarter. Perceptive Advisors LLC now owns 1,784,393 shares of the company’s stock worth $31,762,000 after purchasing an additional 1,629,027 shares during the period. Vestal Point Capital LP increased its holdings in Alto Neuroscience by 161.6% in the fourth quarter. Vestal Point Capital LP now owns 2,485,000 shares of the company’s stock valued at $44,233,000 after purchasing an additional 1,535,000 shares during the last quarter. Spruce Street Capital LP increased its holdings in Alto Neuroscience by 494.7% in the first quarter. Spruce Street Capital LP now owns 1,325,210 shares of the company’s stock valued at $29,116,000 after purchasing an additional 1,102,366 shares during the last quarter. Finally, Vivo Capital LLC acquired a new position in Alto Neuroscience in the fourth quarter valued at about $18,433,000.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.